Feuerstein's Biotech-Stock Mailbag
BOSTON -- Thanks for returning to the Biotech Mailbag. I do my best to respond to your comments and questions, so please email me here.
This week's Mailbag:
Synta Pharmaceuticals (SNTA)Repros Therapeutics (RPRX) and Indevus Pharmaceuticals (IDEV) PDL BioPharma (PDLI)
Everyone loves a chuckle, especially on a Saturday, so let's kick off with a very funny letter from a guy who identifies himself as "G F Urself." Apparently, Mr. Urself is a bit peeved at something I said in last week's Mailbag about Biogen Idec. (I wonder what G F stands for?) I wrote: "And what happens if another fatal or disabling case of progressive multifocal leukoencephalopathy (PML) crops up in a Tysabri patient? I guess I'm on the fence about Biogen Idec." To which, Mr. Urself emailed to me: "How about you 'guess' you are and have been a disingenuous hatchet shill, bought and paid for by a competitor that produces a drug that tries to compete in the mktplace [sic] with Tysabri? I'll continue to enjoy watching the user numbers and their inexorable climb upward at the expense of your handler's offerings; it is inevitable ... Shalom Ahole [sic.]" Apparently, someone forget to take their meds ... I don't know if Urself is an investor in Biogen Idec or Tysabri marketing partner Elan (I'm guessing the latter) but if he does own Biogen Idec, he's one happy (albeit still twisted) camper this morning after the big news that broke Friday night.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV